US EditionWallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
- WallachBeth Capital LLC announced that bioAffinity Technologies, Inc. will sell 720,000 shares of common stock at $2.50 each in a registered direct offering under Nasdaq rules.
- The expected gross proceeds from the offering are approximately $1.8 million before expenses.
- BioAffinity Technologies intends to use the net proceeds for working capital and to support sales of its noninvasive lung cancer test, CyPath® Lung.
- The common stock offering is conducted under a 'shelf' registration statement filed with the U.S. Securities and Exchange Commission.
27 Articles
27 Articles
Bennington Banner
WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
JERSEY CITY, N.J., Oct. 8, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests…
CNHI News
waynecountynews.comWallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
JERSEY CITY, N.J., Oct. 9, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests…
bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies (NASDAQ: BIAF) announced on October 9, 2025 that it closed a registered direct offering of 720,000 common shares at $2.50 per share, raising approximately $1.8 million before offering expenses. WallachBeth Capital acted as sole placement agent. The company said net proceeds will be used for working capital, to support expected growing sales of CyPath® Lung, and for general corporate purposes. The shares were offered unde…
Coverage Details
Bias Distribution
- 70% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
